Most people think of heart disease, kidney disease and diabetes as separate problems. In reality, they are tightly ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — In this Healio video exclusive, Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, presents updated ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Chiadi E. Ndumele, ...

Please provide your email address to receive an email when new articles are posted on . In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nihar R. Desai, MD ...

In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.

SGLT2 inhibitors were associated with significantly lower risks of kidney failure, cardiovascular events, mortality, and hepatic decompensation.

GREENWICH, Conn.--(BUSINESS WIRE)--Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced that the Japanese Patent Office has issued Japanese Patent No. 7474463 ...

Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now ...

India faces a rapidly evolving cardiometabolic risk landscape, with overweight and obesity affecting 23.5% and 6.7% of adults ...